Home > Insider Trading > Filing (0000919574-13-006733)

Filing Details

Accession Number:: 0000919574-13-006733
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-11-15 19:28:35
Reporting Period:: 2013-11-14

Filing Date:: 2013-11-15
Accepted Time:: 2013-11-15 19:28:35
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
891288	Questcor Pharmaceuticals Inc	QCOR	Pharmaceutical Preparations (2834)	330476164

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1278388	C Neal Bradsher	C/O Broadwood Capital Inc. 724 Fifth Avenue, 9Th Floor New York NY 10019		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2013-11-14	15,000	$0.90	19,183	No	4	M	Direct
Common Stock	Acquisiton	2013-11-14	25,000	$0.83	44,183	No	4	M	Direct
Common Stock	Disposition	2013-11-14	15,000	$62.31	29,183	No	4	S	Direct
Common Stock	Disposition	2013-11-14	25,000	$62.46	4,183	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	OPTION TO PURCHASE COMMON SHARES	Disposition	2013-11-14	15,000	$0.00	15,000	$0.90
Common Shares	OPTION TO PURCHASE COMMON SHARES	Disposition	2013-11-14	25,000	$0.00	25,000	$0.83

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2014-03-25	No	4	M	Direct
0		2014-03-09	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	2,796,660	Indirect	Footnote

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Shares	OPTION TO PURCHASE COMMON SHARES	$34.86	2023-05-24	9,203	9,203	Direct
Common Shares	OPTION TO PURCHASE COMMON SHARES	$40.37	2022-05-09	15,214	15,214	Direct
Common Shares	OPTION TO PURCHASE COMMON SHARES	$14.73	2020-12-31	17,500	17,500	Direct
Common Shares	OPTION TO PURCHASE COMMON SHARES	$14.73	2020-12-31	15,000	15,000	Direct
Common Shares	OPTION TO PURCHASE COMMON SHARES	$4.75	2019-12-31	17,500	17,500	Direct
Common Shares	OPTION TO PURCHASE COMMON SHARES	$4.75	2019-12-31	15,000	15,000	Direct
Common Shares	OPTION TO PURCHASE COMMON SHARES	$9.31	2018-12-31	32,500	32,500	Direct
Common Shares	OPTION TO PURCHASE COMMON SHARES	$5.77	2017-12-31	32,500	32,500	Direct
Common Shares	OPTION TO PURCHASE COMMON SHARES	$1.47	2016-12-31	32,500	32,500	Direct
Common Shares	OPTION TO PURCHASE COMMON SHARES	$1.04	2015-12-31	32,500	32,500	Direct
Common Shares	OPTION TO PURCHASE COMMON SHARES	$0.53	2014-12-31	32,500	32,500	Direct
Common Shares	OPTION TO PURCHASE COMMON SHARES	$0.84	2014-05-16	7,500	7,500	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2023-05-24	9,203	9,203	Direct
2022-05-09	15,214	15,214	Direct
2020-12-31	17,500	17,500	Direct
2020-12-31	15,000	15,000	Direct
2019-12-31	17,500	17,500	Direct
2019-12-31	15,000	15,000	Direct
2018-12-31	32,500	32,500	Direct
2017-12-31	32,500	32,500	Direct
2016-12-31	32,500	32,500	Direct
2015-12-31	32,500	32,500	Direct
2014-12-31	32,500	32,500	Direct
2014-05-16	7,500	7,500	Direct

Footnotes

This constitutes the weighted average sale price. The prices range from $62.31 to $62.39. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
This constitutes the weighted average sale price. The prices range from $62.46 to $62.54. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
These securities are owned by Neal C. Bradsher, who is the Reporting Person.
The reported securities are directly owned by Broadwood Partners, L.P. and may be deemed beneficially owned by Broadwood Capital, Inc. as General Partner of Broadwood Partners, L.P. and Neal C. Bradsher as President of Broadwood Capital, Inc. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Includes a restricted stock award of 4,183 shares granted to Neal C. Bradsher on May 24, 2013 under the Questcor Pharmaceuticals, Inc. (the "Company") 2006 Equity Incentive Award Plan, and that were inadvertently omitted from Form 4 filings made by Broadwood Partners, L.P. on June 17th, 2013 and November 13th, 2013. The shares will vest in full upon the earlier to occur of (i) May 24th, 2014 or (ii) the Company's 2014 Annual Shareholders' Meeting.
These options are currently exercisable.
Options granted under the Questcor Pharmaceuticals, Inc. 1992 Employee Stock Option Plan.
These options vest in equal monthly installments over one year from the time of the grant.
These options vest monthly over 48 months from the time of the grant.